Literature DB >> 21665246

Changing trends in the epidemiology of pyogenic vertebral osteomyelitis: the impact of cases with no microbiologic diagnosis.

Jaime Lora-Tamayo1, Gorane Euba, José A Narváez, Oscar Murillo, Ricard Verdaguer, Beatriz Sobrino, Javier Narváez, Joan M Nolla, Javier Ariza.   

Abstract

OBJECTIVES: The observed higher incidence of pyogenic vertebral osteomyelitis (PVO) may entail an increasing number of patients with no microbiologic diagnosis. The true incidence of these cases, how exhaustive the etiologic diagnostic efforts must be, and the usefulness of an empirical antibiotic therapy are not well defined.
METHODS: Retrospective analysis of all cases of vertebral osteomyelitis in our center (1991-2009) and retrospective analysis of cases of PVO (2005-2009). Clinical data, diagnostic procedures, treatment, and outcome were reviewed. A comparative analysis between microbiologically confirmed PVO (MCPVO) and probable PVO (PPVO) was performed.
RESULTS: Increasing incidence of PVO (+0.047 episodes/100,000 inhabitants-year). During the last decade, there was an increase of PPVO (+0.059 episodes/100,000 inhabitants-year) with stable incidence of MCPVO. During 2005-2009, there were 72 patients [47 (65%) MCPVO and 25 (35%) PPVO]. 60% men; mean age was 66 years. Bacteremia was found in 59%. Computed tomographic guided vertebral biopsy, positive in 7/36 (19%), was more successful among patients with bacteremia. Among MCPVO, there was an increasing proportion of less virulent bacteria. Cases of MCPVO presented more frequently with sepsis, fever, and high acute-phase reactants, and PPVO cases were mostly treated with oral fluoroquinolones plus rifampin. No differences were found between both groups in outcome (93% success, 22% sequelae).
CONCLUSIONS: An epidemiologic change of PVO is suggested by a higher incidence of PPVO and the isolation of less virulent microorganisms among MCPVO. In this setting, the availability of an oral and effective empirical antibiotic therapy may challenge an exhaustive prosecution of the etiology.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21665246     DOI: 10.1016/j.semarthrit.2011.04.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  32 in total

1.  Factors influencing culture positivity in pyogenic vertebral osteomyelitis patients with prior antibiotic exposure.

Authors:  Chung-Jong Kim; Seung-Ji Kang; Doran Yoon; Myung Jin Lee; Moonsuk Kim; Kyoung-Ho Song; Hee-Chang Jang; Sook-In Jung; Eu Suk Kim; Hong Bin Kim; Myoung-Don Oh; Kyung-Hwa Park; Nam Joong Kim
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Risk factors and prognosis of vertebral compressive fracture in pyogenic vertebral osteomyelitis.

Authors:  Alba Ribera; Maria Labori; Javier Hernández; Jaime Lora-Tamayo; Lluís González-Cañas; Federic Font; Joan M Nolla; Javier Ariza; José A Narváez; Oscar Murillo
Journal:  Infection       Date:  2015-06-06       Impact factor: 3.553

3.  Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009.

Authors:  Hilal Maradit Kremers; Macaulay E Nwojo; Jeanine E Ransom; Christina M Wood-Wentz; L Joseph Melton; Paul M Huddleston
Journal:  J Bone Joint Surg Am       Date:  2015-05-20       Impact factor: 5.284

4.  Susceptibility Pattern of Microorganisms Isolated by Percutaneous Needle Biopsy in Nonbacteremic Pyogenic Vertebral Osteomyelitis.

Authors:  Sophie Desoutter; Jean-Philippe Cottier; Idir Ghout; Bertrand Issartel; Aurélien Dinh; Arnaud Martin; Robert Carlier; Louis Bernard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

5.  Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients.

Authors:  Enrico Pola; F Taccari; G Autore; F Giovannenze; V Pambianco; R Cauda; G Maccauro; M Fantoni
Journal:  Eur Spine J       Date:  2018-04-17       Impact factor: 3.134

6.  Joint EANM/ESNR and ESCMID-endorsed consensus document for the diagnosis of spine infection (spondylodiscitis) in adults.

Authors:  Elena Lazzeri; Alessandro Bozzao; Maria Adriana Cataldo; Nicola Petrosillo; Luigi Manfrè; Andrej Trampuz; Alberto Signore; Mario Muto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-09       Impact factor: 9.236

7.  An inter- and intra-rater agreement assessment of a novel classification of pyogenic spinal infections.

Authors:  Gaston Camino-Willhuber; Byron Delgado; Nelson Astur; Alfredo Guiroy; Marcelo Valacco; Luigi Aurelio Nasto; Luca Piccone; Giovanni Barbanti-Brodano; Antonio Leone; Valerio Cipolloni; Enrico Pola; Julio Urrutia
Journal:  Eur Spine J       Date:  2022-01-10       Impact factor: 3.134

8.  CORR Insights®: Treatment Guideline for Patients with Native Culture-negative Pyogenic Vertebral Osteomyelitis.

Authors:  Panagiotis Korovessis
Journal:  Clin Orthop Relat Res       Date:  2022-01-01       Impact factor: 4.755

9.  Operative Treatment of Adult Pyogenic Spondylodiscitis: A Retrospective Study of 32 Cases.

Authors:  Frideriki Poutoglidou; Dimitrios Metaxiotis; Panagiotis Saloupis; Anastasios Mpeletsiotis
Journal:  Cureus       Date:  2021-05-03

10.  Treatment Guideline for Patients with Native Culture-negative Pyogenic Vertebral Osteomyelitis.

Authors:  Seung Hun Lee; Jihye Kim; Tae-Hwan Kim
Journal:  Clin Orthop Relat Res       Date:  2022-01-01       Impact factor: 4.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.